These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18611220)

  • 1. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro).
    Bacha U; Barrila J; Gabelli SB; Kiso Y; Mario Amzel L; Freire E
    Chem Biol Drug Des; 2008 Jul; 72(1):34-49. PubMed ID: 18611220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS).
    St John SE; Tomar S; Stauffer SR; Mesecar AD
    Bioorg Med Chem; 2015 Sep; 23(17):6036-48. PubMed ID: 26190463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.
    Berry M; Fielding BC; Gamieldien J
    Viruses; 2015 Dec; 7(12):6642-60. PubMed ID: 26694449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.
    Konno H; Wakabayashi M; Takanuma D; Saito Y; Akaji K
    Bioorg Med Chem; 2016 Mar; 24(6):1241-54. PubMed ID: 26879854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.
    Teruya K; Hattori Y; Shimamoto Y; Kobayashi K; Sanjoh A; Nakagawa A; Yamashita E; Akaji K
    Biopolymers; 2016 Nov; 106(4):391-403. PubMed ID: 26572934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-Ray Structure and Inhibition of 3C-like Protease from Porcine Epidemic Diarrhea Virus.
    St John SE; Anson BJ; Mesecar AD
    Sci Rep; 2016 May; 6():25961. PubMed ID: 27173881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.
    Galasiti Kankanamalage AC; Kim Y; Weerawarna PM; Uy RA; Damalanka VC; Mandadapu SR; Alliston KR; Mehzabeen N; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2015 Apr; 58(7):3144-55. PubMed ID: 25761614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies.
    Dampalla CS; Nguyen HN; Rathnayake AD; Kim Y; Perera KD; Madden TK; Thurman HA; Machen AJ; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    ACS Pharmacol Transl Sci; 2023 Jan; 6(1):181-194. PubMed ID: 36654747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
    Bai B; Arutyunova E; Khan MB; Lu J; Joyce MA; Saffran HA; Shields JA; Kandadai AS; Belovodskiy A; Hena M; Vuong W; Lamer T; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    RSC Med Chem; 2021 Oct; 12(10):1722-1730. PubMed ID: 34778773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.
    Suwannarach N; Kumla J; Sujarit K; Pattananandecha T; Saenjum C; Lumyong S
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32295300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo design of SARS-CoV-2 main protease inhibitors with characteristic binding modes.
    Zhu Y; Meng J; Feng B; Zhao Y; Zang Y; Lu L; Su M; Yang Q; Zhang Q; Feng L; Zhao J; Shao M; Ma Y; Yang X; Yang H; Li J; Jiang X; Rao Z
    Structure; 2024 Jun; ():. PubMed ID: 38925121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host specific sensing of coronaviruses and picornaviruses by the CARD8 inflammasome.
    Tsu BV; Agarwal R; Gokhale NS; Kulsuptrakul J; Ryan AP; Castro LK; Beierschmitt CM; Turcotte EA; Fay EJ; Vance RE; Hyde JL; Savan R; Mitchell PS; Daugherty MD
    bioRxiv; 2022 Sep; ():. PubMed ID: 36172130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies.
    Dampalla CS; Kim Y; Zabiegala A; Howard DJ; Nguyen HN; Madden TK; Thurman HA; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2024 Jul; ():. PubMed ID: 38953866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead".
    Elshan NGRD; Wolff KC; Riva L; Woods AK; Grabovyi G; Wilson K; Pedroarena J; Ghorai S; Nazarian A; Weiss F; Liu Y; Mazumdar W; Song L; Okwor N; Malvin J; Liu D; Bakowski MA; Beutler N; Kirkpatrick MG; Gebara-Lamb A; Huang E; Nguyen-Tran VTB; Chi V; Li S; Rogers TF; McNamara CW; Gupta AK; Rahimi A; Chen JJ; Joseph SB; Schultz PG; Chatterjee AK
    J Med Chem; 2024 Jun; 67(12):10508-10509. PubMed ID: 38875353
    [No Abstract]   [Full Text] [Related]  

  • 15. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor.
    Ohnishi K; Hattori Y; Kobayashi K; Akaji K
    Bioorg Med Chem; 2019 Jan; 27(2):425-435. PubMed ID: 30558861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor.
    Konno H; Onuma T; Nitanai I; Wakabayashi M; Yano S; Teruya K; Akaji K
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2746-2751. PubMed ID: 28454669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
    Konno S; Thanigaimalai P; Yamamoto T; Nakada K; Kakiuchi R; Takayama K; Yamazaki Y; Yakushiji F; Akaji K; Kiso Y; Kawasaki Y; Chen SE; Freire E; Hayashi Y
    Bioorg Med Chem; 2013 Jan; 21(2):412-24. PubMed ID: 23245752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and common inhibitors of coronavirus and picornavirus main proteases.
    Kuo CJ; Liu HG; Lo YK; Seong CM; Lee KI; Jung YS; Liang PH
    FEBS Lett; 2009 Feb; 583(3):549-55. PubMed ID: 19166843
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.